Patrick J. Maguire
Chief Tech/Sci/R&D Officer at Eleison Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edwin J. Thomas | M | 65 |
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 15 years |
| Troy Barring | M | - |
HemoLife Medical, Inc.
 HemoLife Medical, Inc. Hospital/Nursing ManagementHealth Services HemoLife Medical, Inc. provides health care services. The company is headquartered in Dana Point, CA. | - |
| Jess Emery Jones | M | 45 | 16 years | |
| Joel Morganroth | M | 78 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 6 years |
| Michael Otto | M | 75 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 5 years |
| Bryan R. Wood | M | 78 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 14 years |
| Scott Humphrey | M | 53 |
HemoLife Medical, Inc.
HemoLife Medical, Inc. Hospital/Nursing ManagementHealth Services HemoLife Medical, Inc. provides health care services. The company is headquartered in Dana Point, CA. | - |
| Michael E. Lusty | M | 61 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 13 years |
| Frank Seidman | M | 71 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 12 years |
| Matthew Allen Cromie | M | 58 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vincent W. Renz | M | 67 | 4 years | |
| Branislav Vajdic | M | 70 | 8 years | |
| James A. Heisch | M | 80 | 3 years | |
| Gregory David Sadowski | M | 51 | - | |
| Michael E. Hanson | M | 74 | - | |
| Robert Blair | M | 81 | 5 years | |
| Mark Kroll | M | 71 | 4 years | |
| Steven A. Marenberg | M | - |
Wesleyan University
| 4 years |
| Richard Brounstein | M | 74 | 4 years | |
| Nathan W. Pearson | M | - |
Wesleyan University
| 5 years |
| Richard Segal | M | - |
Wesleyan University
| 3 years |
| Kathleen A. Walsh | F | - | - | |
| Mark Schonberger | M | - |
Wesleyan University
| 4 years |
| Craig Tighe | M | - |
Wesleyan University
| 3 years |
| Jonathan C. Guest | M | - |
Wesleyan University
| 4 years |
| Jerry Israel | M | 81 |
Wesleyan University
| 14 years |
| James Hope | M | - |
Wesleyan University
| 4 years |
| Gilbert V. Molina | M | - | - | |
| Sandy J. Winer | M | - |
Wesleyan University
| 4 years |
| Philip J. Rauch | M | - |
Wesleyan University
| 4 years |
| Charisse Lillie | F | 71 |
Wesleyan University
| 4 years |
| Paul V. Bennett | M | 70 |
Wesleyan University
| 4 years |
| Chris S. Coutroulis | M | - |
Wesleyan University
| 4 years |
| Stephen Diaz Gavin | M | - |
Wesleyan University
| 4 years |
| Sara G. Schnorr | F | - |
Wesleyan University
| 1 years |
| Marcia DeForest | F | - |
Wesleyan University
| 4 years |
| Thomas Christopher O'Brien | M | - |
Wesleyan University
| 4 years |
| Ron Bloom | M | 69 |
Wesleyan University
| 4 years |
| David Carlisle | M | - |
Wesleyan University
| 4 years |
| William Fricker | M | 60 |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | 1 years |
| Timothy Warner | M | 73 |
Wesleyan University
| 4 years |
| Robert Glasspiegel | M | - |
Wesleyan University
| 4 years |
| John William Petchler | M | - |
Wesleyan University
| 4 years |
| Sam W. Murphy | M | - |
Wesleyan University
| 4 years |
| Bruce Lawrence Tyson | M | 71 |
Wesleyan University
| 4 years |
| Samuel Liss | M | 67 |
Wesleyan University
| 4 years |
| Donald Paul Spencer | M | 69 |
Wesleyan University
| 4 years |
| David C. Moffenbeier | M | - |
Wesleyan University
| 4 years |
| Charles A. James | M | 70 |
Wesleyan University
| 4 years |
| Strauss Zelnick | M | 66 |
Wesleyan University
| 4 years |
| Harold Jay Levy | M | 70 |
Wesleyan University
| 4 years |
| John Michael Shapiro | M | - |
Wesleyan University
| 4 years |
| Kenneth Londoner | M | 57 | 2 years | |
| Jeffrey L. Shames | M | 68 |
Wesleyan University
| 4 years |
| David Weild | M | 67 |
Wesleyan University
| 4 years |
| Robert Beck | M | - |
Wesleyan University
| 4 years |
| Stephen C. Ferruolo | M | - |
Wesleyan University
| 4 years |
| Gail Marcus | M | 67 |
Wesleyan University
| 4 years |
| Ioannis Pechlivanidis | M | - |
Wesleyan University
| 4 years |
| David Schenkein | M | 66 |
Wesleyan University
| 4 years |
| Terrence L. Shockley | M | - |
Wesleyan University
| 4 years |
| George A. Lehner | M | - |
Wesleyan University
| 4 years |
| Stephen J. Imbriglia | M | - |
Wesleyan University
| 4 years |
| Jonathan B. Eddison | M | - |
Wesleyan University
| 4 years |
| Stuart H. Coleman | M | 69 |
Wesleyan University
| 4 years |
| David E. Reisner | M | - |
Wesleyan University
| 3 years |
| Konrad J. Friedemann | M | - |
Wesleyan University
| 4 years |
| Steve Winograd | M | - |
Wesleyan University
| 5 years |
| Tom J. A. Lavin | M | - |
Wesleyan University
| 3 years |
| John Frank | M | - |
Wesleyan University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 70 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick J. Maguire
- Personal Network
